Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 253

1.

Feasibility and acceptability of a culturally adapted advance care planning intervention for people living with advanced cancer and their families: A mixed methods study.

Lin CP, Evans CJ, Koffman J, Chen PJ, Hou MF, Harding R.

Palliat Med. 2020 Feb 21:269216320902666. doi: 10.1177/0269216320902666. [Epub ahead of print]

PMID:
32081076
2.

Effects of different reminder strategies on first-time mammography screening among women in Taiwan.

Lin ML, Huang JJ, Li SH, Lee FH, Hou MF, Wang HH.

BMC Health Serv Res. 2020 Feb 12;20(1):114. doi: 10.1186/s12913-020-4948-6.

3.

Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer.

Pan MR, Wu CC, Kan JY, Li QL, Chang SJ, Wu CC, Li CL, Ou-Yang F, Hou MF, Yip HK, Luo CW.

Cancers (Basel). 2019 Dec 30;12(1). pii: E94. doi: 10.3390/cancers12010094.

4.

A functional variant near XCL1 gene improves breast cancer survival via promoting cancer immunity.

Chou WC, Hsiung CN, Chen WT, Tseng LM, Wang HC, Chu HW, Hou MF, Yu JC, Shen CY.

Int J Cancer. 2020 Apr 15;146(8):2182-2193. doi: 10.1002/ijc.32855. Epub 2020 Jan 25.

PMID:
31904872
5.

Visfatin Mediates Malignant Behaviors through Adipose-Derived Stem Cells Intermediary in Breast Cancer.

Huang JY, Wang YY, Lo S, Tseng LM, Chen DR, Wu YC, Hou MF, Yuan SF.

Cancers (Basel). 2019 Dec 20;12(1). pii: E29. doi: 10.3390/cancers12010029.

6.

Use of Extended Pedicled Transverse Rectus Abdominis Myocutaneous Flap for Extensive Chest Wall Defect Reconstruction After Mastectomy for Locally Advanced Breast Cancer.

Lin YN, Ou-Yang F, Hsieh MC, Lee SS, Huang SH, Chuang CH, Chang CH, Kuo YR, Hou MF, Lin SD.

Ann Plast Surg. 2020 Jan;84(1S Suppl 1):S34-S39. doi: 10.1097/SAP.0000000000002188.

PMID:
31800552
7.

Identification of CHD4-β1 integrin axis as a prognostic marker in triple-negative breast cancer using next-generation sequencing and bioinformatics.

Ou-Yang F, Pan MR, Chang SJ, Wu CC, Fang SY, Li CL, Hou MF, Luo CW.

Life Sci. 2019 Dec 1;238:116963. doi: 10.1016/j.lfs.2019.116963. Epub 2019 Oct 19.

PMID:
31639396
8.

Identification of Prognostic Candidate Genes in Breast Cancer by Integrated Bioinformatic Analysis.

Wang CCN, Li CY, Cai JH, Sheu PC, Tsai JJP, Wu MY, Li CJ, Hou MF.

J Clin Med. 2019 Aug 2;8(8). pii: E1160. doi: 10.3390/jcm8081160.

9.

Differential Response of Non-cancerous and Malignant Breast Cancer Cells to Conditioned Medium of Adipose tissue-derived Stromal Cells (ASCs).

Wu YC, Wang WT, Huang LJ, Cheng RY, Kuo YR, Hou MF, Lai CS, Yu J.

Int J Med Sci. 2019 Jun 2;16(6):893-901. doi: 10.7150/ijms.27125. eCollection 2019.

10.

Accuracy and outcomes of stereotactic vacuum-assisted breast biopsy for diagnosis and management of nonpalpable breast lesions.

Tsai HY, Chao MF, Ou-Yang F, Kan JY, Hsu JS, Hou MF, Chiu HC.

Kaohsiung J Med Sci. 2019 Oct;35(10):640-645. doi: 10.1002/kjm2.12100. Epub 2019 Jul 4.

11.

Ethyl acetate extract of Nepenthes adrianii x clipeata induces antiproliferation, apoptosis, and DNA damage against oral cancer cells through oxidative stress.

Tang JY, Peng SY, Cheng YB, Wang CL, Farooqi AA, Yu TJ, Hou MF, Wang SC, Yen CH, Chan LP, Ou-Yang F, Chang HW.

Environ Toxicol. 2019 Aug;34(8):891-901. doi: 10.1002/tox.22748. Epub 2019 Jun 3.

PMID:
31157515
12.

Relationship between Clinicopathologic Variables in Breast Cancer Overall Survival Using Biogeography-Based Optimization Algorithm.

Chuang LY, Chen GY, Moi SH, Ou-Yang F, Hou MF, Yang CH.

Biomed Res Int. 2019 Apr 1;2019:2304128. doi: 10.1155/2019/2304128. eCollection 2019.

13.

Cell Reprogramming in Tumorigenesis and Its Therapeutic Implications for Breast Cancer.

Chu PY, Hou MF, Lai JC, Chen LF, Lin CS.

Int J Mol Sci. 2019 Apr 12;20(8). pii: E1827. doi: 10.3390/ijms20081827. Review.

14.

YWHAE promotes proliferation, metastasis, and chemoresistance in breast cancer cells.

Yang YF, Lee YC, Wang YY, Wang CH, Hou MF, Yuan SF.

Kaohsiung J Med Sci. 2019 Jul;35(7):408-416. doi: 10.1002/kjm2.12075. Epub 2019 Apr 18.

15.

New Insight on Solute Carrier Family 27 Member 6 (SLC27A6) in Tumoral and Non-Tumoral Breast Cells.

Yen MC, Chou SK, Kan JY, Kuo PL, Hou MF, Hsu YL.

Int J Med Sci. 2019 Jan 24;16(3):366-375. doi: 10.7150/ijms.29946. eCollection 2019.

16.

FAK is Required for Tumor Metastasis-Related Fluid Microenvironment in Triple-Negative Breast Cancer.

Pan MR, Hou MF, Ou-Yang F, Wu CC, Chang SJ, Hung WC, Yip HK, Luo CW.

J Clin Med. 2019 Jan 2;8(1). pii: E38. doi: 10.3390/jcm8010038.

17.

Solute Carrier Family 27 Member 4 (SLC27A4) Enhances Cell Growth, Migration, and Invasion in Breast Cancer Cells.

Yen MC, Chou SK, Kan JY, Kuo PL, Hou MF, Hsu YL.

Int J Mol Sci. 2018 Nov 1;19(11). pii: E3434. doi: 10.3390/ijms19113434.

18.

The effect of NSAIDs exposure on breast cancer risk in female patients with autoimmune diseases.

Hung CH, Lin YC, Chang YH, Lin YC, Huang HY, Yeh WJ, Wu TY, Hou MF.

Eur J Cancer Prev. 2019 Sep;28(5):428-434. doi: 10.1097/CEJ.0000000000000476.

PMID:
30339576
19.

Breast cancer is associated with methylation and expression of the a disintegrin and metalloproteinase domain 33 (ADAM33) gene affected by endocrine‑disrupting chemicals.

Yang PJ, Hou MF, Tsai EM, Liang SS, Chiu CC, Ou-Yang F, Kan JY, Peng CY, Wang TN.

Oncol Rep. 2018 Nov;40(5):2766-2777. doi: 10.3892/or.2018.6675. Epub 2018 Aug 30.

PMID:
30226539
20.

Oxidative stress-modulating drugs have preferential anticancer effects - involving the regulation of apoptosis, DNA damage, endoplasmic reticulum stress, autophagy, metabolism, and migration.

Tang JY, Ou-Yang F, Hou MF, Huang HW, Wang HR, Li KT, Fayyaz S, Shu CW, Chang HW.

Semin Cancer Biol. 2019 Oct;58:109-117. doi: 10.1016/j.semcancer.2018.08.010. Epub 2018 Aug 24. Review.

PMID:
30149066

Supplemental Content

Loading ...
Support Center